The CDTM is an extension of the traditional practice of pharmacists, which helps to manage drug-related problems (PDs) led by pharmacists, with an emphasis on a collaborative and interdisciplinary approach to pharmacy practice in the health sector. The conditions of a CPA are defined by the pharmacist and the cooperating physician, although models exist online. CPAs may be specific to a patient population of interest to both parties, a specific clinical situation or disease, and/or a factual protocol for managing the drug treatment of patients under CPA. CPAs have been the subject of intensive debate in pharmacy and medicine. A Collaborative Practice Agreement (CPA) is a legal document in the United States that establishes a legal relationship between clinical pharmacists and cooperating physicians, which allows pharmacists to participate in the collaborative management of drug therapy (CDTM). In 2015, the American College of Clinical Pharmacy (ACCP) published an updated white paper on the management of collaborative drug therapy. CacP regularly publishes updates on this topic, with previous publications in 2003 and 1997. The document describes the recent history of CPAs, legislative advances and discussed payment models for collaborative drug therapy management activities.  Although CPAs are not a prerequisite for the provision of collaborative care, they can be used to improve the efficiency and effectiveness of collaborative care delivery. If they are used to their full potential, CPAs have the opportunity to improve access to medical care, expand services available to patients, improve efficiency and coordination of care, and use the expertise of pharmacists in drug matters to complement the skills and knowledge of other members of the health team.
This toolkit was developed by ChangeLab Solutions, the Centers for Disease Control and Prevention (CDC), the National Alliance of State Pharmacy Associations (NASPA) and the American Pharmacists Association (APhA) as part of a cooperation agreement with ChangeLab Solutions. State laws may differ from whether CPAs apply to individual or multiple patients, are limited to certain practical parameters, in which they are allowed to enter (. B for example, all doctors subject to medical prescription, doctors and nurses only), the qualifications of pharmacists (for example. B approved by state bodies or registered with state bodies, PharmD, continuing education) and much more. Some states require parties to take out liability insurance or an invalid rebate after a period of time. Collaborative Practice Agreements (CPAs) create formal practical relationships between pharmacists and prescribers. CPAs can use collaborative care by defining functions that, in addition to the typical pharmacist`s practice, are delegated to the pharmacist by the co-operative prescriber under negotiated terms defined in the agreement. In 2010, the American Medical Association (AMA) published a series of reports entitled „AMA Scope of Practice Data Series.“  One report focused on the pharmacy profession, which criticized the formation of CPAs as an attempt by pharmacists to intervene with the physician.
In response to the report, a collaboration of seven national pharmacists` associations prepared a response to the WADA Pharmacists Report.  The response called on WADA to correct its report and publish the revised report with Errata.  In 2011, THE WADA Chamber of Deputies adopted a softer tone of the APhA in response to contributions from aPhA and other professional organizations, Finally, the following resolution, which focused attention on the rejection of independent (non-collaborative or dependent) practical agreements: that our WADA develop model government legislation to combat the extension of pharmacists` practice, which is considered inappropriate or constitutes the practice of medicine, including, but not limited to, the question of the interpretation or use of independent practice agreements without adequate medical supervision, and to cooperate with states and relevant specialties to advance this legislation (rich.
43total visits,1visits today